Bupropion for the treatment of nicotine withdrawal and craving

@article{Mooney2006BupropionFT,
  title={Bupropion for the treatment of nicotine withdrawal and craving},
  author={Marc E. Mooney and Mehmet Sofuoglu},
  journal={Expert Review of Neurotherapeutics},
  year={2006},
  volume={6},
  pages={965 - 981}
}
Over the past decade, bupropion has become a major pharmacotherapy for smoking cessation in the Western world. Unlike other smoking cessation pharmacotherapies, bupropion is a non-nicotine treatment. Compared with a placebo control, bupropion approximately doubles smoking quit rates. Most smoking cessation pharmacotherapies are thought to work, in part, by reducing nicotine withdrawal and craving. This article reviews preclinical, human laboratory and clinical trial studies of the effect of… 
Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent.
TLDR
Clinically, bupropion is used as a treatment for two indications, as an antidepressant, the indication for which it was developed, and as a tobacco use cessation agent and is being tested as a candidate treatment for psychostimulant drug abuse, attention-deficit hyperactivity disorder (ADHD) and obesity.
Effect of stress and bupropion on craving, withdrawal symptoms, and mood in smokers.
  • M. Kotlyar, David Drone, M. al’Absi
  • Psychology, Medicine
    Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco
  • 2011
TLDR
It is demonstrated that stress results in sustained increases in craving and withdrawal symptoms and changes in mood symptoms and that bupropion affects overall levels of these symptoms.
Intention to quit moderates the effect of bupropion on smoking urge.
  • J. Tidey, D. Rohsenow
  • Psychology
    Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco
  • 2009
TLDR
This study is one of the first placebo-controlled examinations of the effects of bupropion on cue reactivity and provides support for the idea that laboratory smoking studies may be more likely to detect effects of pharmacological treatments for smoking when they enroll smokers who intend to quit.
Pharmacotherapy for smoking cessation: present and future.
TLDR
Clinicians should encourage and offer counseling and a prescription of pharmacotherapy to every patient willing to make a quit attempt and a series of promising drugs that hopefully will be available to complete the current armory.
Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice
TLDR
An overview of pipeline developments and issues related to smoking cessation in special populations such as persons with psychiatric comorbidity and pregnant and adolescent smokers and regulatory agencies consider these drugs as having a favourable benefit/risk profile.
Bupropion and naltrexone for smoking cessation: A double‐blind randomized placebo‐controlled clinical trial
TLDR
The BUP + NTX combination was associated with elevated rates of some side effects, but with no significant difference in retention between the groups, and those receiving BUP+ NTX reported reduced nicotine withdrawal.
Cannabidiol reduces withdrawal symptoms in nicotine-dependent rats.
TLDR
Using CBD as a strategy to alleviate the withdrawal symptoms upon nicotine cessation may be beneficial, and a ceiling effect at the doses used and the potential for lower effective doses of CBD are suggested.
Bupropion increases activation in nucleus accumbens during anticipation of monetary reward
TLDR
Investigation of the effects of single-dose administration of bupropion on neural response of reward anticipation in healthy subjects using a monetary incentive delay (MID) task by functional magnetic resonance imaging (fMRI) found that buPropion significantly increased BOLD responses in NAc during monetary reward anticipation.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 150 REFERENCES
The effect of bupropion on nicotine craving and withdrawal
TLDR
Bupropion significantly reduced abstinence-associated increases in rated depression, difficulty concentrating, and irritability, and attenuated a decrease in positive affect, and suggested that bupropion might have a positive effect on performance measures during the withdrawal period.
Effect of bupropion on depression symptoms in a smoking cessation clinical trial.
  • C. Lerman, R. Niaura, L. Epstein
  • Psychology
    Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors
  • 2004
TLDR
Depression symptoms did not mediate the effects of bupropion on abstinence at either time point and a regression model of depression symptoms demonstrated a significant interaction between nicotine dependence and treatment for the treatment phase and during follow-up.
The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline
  • J. Foulds
  • Medicine, Biology
    International journal of clinical practice
  • 2006
TLDR
Varenicline, a specific α4β2 nicotinic receptor partial agonist, is a new pharmacotherapy that stimulates dopamine and simultaneously blocks nicotine receptors that could be an important advance in the treatment of nicotine dependence.
Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat
TLDR
Bupropion acts on multiple levels to alter brain reward circuits influenced by nicotine, in addition to reducing the expression of somatic signs of withdrawal, which is likely to act in concert to mediate the unique anti-smoking properties of bupropion.
How does bupropion work as a smoking cessation aid?
TLDR
The principal mode of bupropion action is upon the withdrawal symptoms following smoking cessation, and during withdrawal, buPropion may attenuate symptoms by mimicking nicotinic effects on dopamine and noradrenaline.
Recommendation for the assessment of tobacco craving and withdrawal in smoking cessation trials.
  • S. Shiffman, R. West, D. Gilbert
  • Psychology
    Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco
  • 2004
TLDR
Assessment of nicotine withdrawal and craving in clinical trials of smoking cessation therapies is addressed; different designs and approaches are needed to investigate the process and natural history of craving and withdrawal.
...
1
2
3
4
5
...